行情

BSTC

BSTC

BioSpecifics生物
NASDAQ

实时行情|Nasdaq Last Sale

52.97
-0.10
-0.19%
已收盘, 16:00 11/14 EST
开盘
53.05
昨收
53.07
最高
53.40
最低
52.70
成交量
4.76万
成交额
--
52周最高
73.31
52周最低
45.81
市值
3.89亿
市盈率(TTM)
16.71
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BSTC 新闻

  • 易车网11月26日发布2019年第三季度财报
  • 新浪科技.1小时前
  • 京东2019第三季度移动端月活跃用户数同比增长36%
  • 新浪科技.1小时前
  • 京东物流外部收入占比近40% 已服务超20万企业用户
  • 新浪科技.1小时前
  • 京东第三季度净收入同比增28.7% 核心指标加速增长
  • 新浪财经.1小时前

更多

所属板块

生物技术和医学研究
-0.05%
制药与医学研究
-0.27%

热门股票

名称
价格
涨跌幅

BSTC 简况

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.
展开

Webull提供BioSpecifics Technologies Corp.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。